Back to results
US 2009/0023719 A1Published application
Pyrimidine derivatives 934
AssigneeAstraZeneca AB
InventorsBernard Christophe Barlaam, Richard Ducray, Jason Grant Kettle
Life of this patent
Estimating the term…
Abstract
A compound of formula (I) where one of A1, A2 or A3 is N, and the others are independently selected from CH or N; ring B is a fused 5 or 6-membered carbocyclic or heterocyclic which is optionally substituted as defined in the specification, and R1, R2, R3, R4, and n are as defined in the specification. The compounds are inhibitors of EphB4 or EphA2 and therefore may be useful in pharmaceutical compositions for the treatment of conditions such as cancer.
Claims16
A compound of formula (I)
- where one of A1, A2 or A3 is N, and the others are independently selected from CH or N;
- R1 is hydrogen or a (1-4C)alkyl group which is optionally substituted by one or more substituent groups selected from —OR5 (wherein R5 is selected from hydrogen or (1-2C)alkyl), cyano, halo, or —NR6R7 (where R6 and R7 are independently selected from hydrogen, (1-2C)alkyl or (1-2C)alkanoyl);
- ring B is a fused 5 or 6-membered carbocyclic or heterocyclic ring which is optionally substituted on a carbon atom by one or more halo groups or C1-6alkyl groups, and where any nitrogen atoms in the ring are optionally substituted by a C1-6alkyl or C1-6alkylcarbonyl;
- n is 0, 1, 2 or 3
- and each group R2 is independently selected from halogeno, trifluoromethyl, cyano, nitro or a group of sub-formula (I):
- —X1—R11 (i)
- where X1 is selected from a direct bond or O, S, SO, SO2, OSO2, NR13, CO, CH(OR13), CONR13, N(R13)CO, SO2N(R13), N(R13)SO2, C(R13)2O, C(R13)2S, C(R13)2N(R13) and N(R13)C(R13)2, wherein R13 is hydrogen or C1-6alkyl and
- R11 is selected from hydrogen, C1-6 alkyl, C2-8alkenyl, C2-8alkynyl, C3-8cycloalkyl, aryl or heterocyclyl, C1-6 alkylC3-8cycloalkyl, C1-6 alkylaryl or C1-6 alkylheterocyclyl, any of which may be optionally substituted with one or more groups selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, C1-6alkoxy, C2-6alkenyoxyl, C2-6alkynyloxy, C1-6alkylthio, C1-6alkylsulphinyl, C1-6alkylsulphonyl, C1-16alkylamino, di-(C1-16alkyl)amino, C1-16alkoxycarbonyl, N—C1-6alkylcarbamoyl, N,N-di-(C1-6alkyl)carbamoyl, C2-6alkanoyl, C2-6alkanoyloxy, C2-6alkanoylamino, N—C1-6alkyl-C2-6alkanoylamino, C3-6alkenoylamino, N—C1-6alkyl-C3-6alkenoylamino, C3-6alkynoylamino, N—C1-6alkyl-C3-6alkynoylamino, N—C1-6alkylsulphamoyl, N,N-di-(C1-6alkyl)sulphamoyl, C1-16alkanesulphonylamino and N—C1-16alkyl-C1-6alkanesulphonylamino, any heterocyclyl group within R11 optionally bears 1 or 2 oxo or thioxo substituents;
- R3 is selected from:
- (i) hydrogen, halo, nitro, cyano, or hydroxy;
- (ii) an optionally substituted (1-6C)alkyl, (2-6C)alkenyl, or (2-6C)alkynyl group wherein the optional substituents are selected from:
- cyano;
- halo;
- a group of sub-formula:
- —W—R9
- wherein W is selected from —O—, —S(O)p— (where p is 0, 1 or 2), —CO—, —NRbCO—, —CONRb—, —NRbCONRb—, —SO2NRb—, —NRbSO2—, or —NRbCOO—;
- Rb is selected from hydrogen or (1-2C)alkyl;
- and R9 is selected from hydrogen or (1-4C)alkyl;
- or —NR10R10a, where R10 and R10a are independently selected from hydrogen, or (1-2C)alkyl, or R10 and R10a are linked to form a 4, 5, 6 or 7 membered heterocyclic ring which optionally comprises, in addition to the nitrogen atom to which R10 and R10a are attached, one or two further heteroatoms selected from O, N or S, and wherein any S atoms that are present may be optionally oxidised to form an SO and SO2 group, and wherein any carbon atom present in the ring is optionally substituted by oxo, halo, hydroxy, cyano, (1-4C)alkyl, hydroxy(1-4C)alkyl, (1-4C)alkoxy, (1-2C)alkoxy-(1-4C)alkyl, (1-4C)alkanoyl, (1-4C)alkanesulfonyl, (1-4C)alkoxycarbonyl, (1-6C)alkylaminocarbonyl or di-(1-6C)alkylaminocarbonyl and any available nitrogen atom present in the ring is optionally substituted by (1-4C)alkyl, hydroxy(1-4C)alkyl, (1-2C)alkoxy-(1-4C)alkyl, or (1-4C)alkanoyl;
- (iii) a group —NR12R12a, wherein R12 and R12a are each independently selected from hydrogen or (1-6C)alkyl, or R12 and R12a are linked to form a 4, 5, 6 or 7-membered heterocyclic ring which optionally comprises, in addition to the nitrogen atom to which R12 and R12a are attached, one or two further heteroatoms selected from O, N or S, and wherein any S atoms that are present may be optionally oxidised to form an SO and SO2 group, and wherein any carbon atom present in the ring is optionally substituted by oxo, halo, hydroxy, cyano, (1-4C)alkyl, hydroxy(1-4C)alkyl, (1-4C)alkoxy, (1-2C)alkoxy-(1-4C)alkyl, (1-4C)alkanoyl, (1-4C)alkanesulfonyl, (1-4C)alkoxycarbonyl, (1-6C)alkylaminocarbonyl or di-(1-6C)alkylaminocarbonyl and any available nitrogen atom present in the ring is optionally substituted by (1-4C)alkyl, hydroxy(1-4C)alkyl, (1-2C)alkoxy-(1-4C)alkyl, or (1-4C)alkanoyl;
- (iv) a group of formula (II):
- —X—R14
- wherein X is selected from —O—, —S(O)p— (where p is 0, 1 or 2), —CO—, —NRcCO—, —CONRc—, —NRcCOO—, and —NRcSO2—,
- where Rc is selected hydrogen or (1-2C)alkyl;
- R14 is a (1-4C)alkyl group which is optionally substituted by halo, hydroxy, cyano, (1-4C)alkoxy, or R14 is
- —NR15R16
- where R15 and R16 are independently selected from hydrogen, (1-2C)alkanoyl or (1-2C)alkyl, or R15 and R16 are linked to form a 4, 5, 6 or 7-membered heterocyclic ring which optionally comprises, in addition to the nitrogen atom to which R15 and R16 are attached, one or two further heteroatoms selected from O, N or S, and wherein any S atoms that are present may be optionally oxidised to form an SO and SO2 group, and wherein any carbon atom present in the ring is optionally substituted by oxo, halo, hydroxy, cyano, (1-4C)alkyl, hydroxy(1-4C)alkyl, (1-4C)alkoxy, (1-2C)alkoxy-(1-4C)alkyl, (1-4C)alkanoyl, (1-4C)alkanesulfonyl, (1-4C)alkoxycarbonyl, (1-6C)alkylaminocarbonyl or di-(1-6C)alkylaminocarbonyl and any available nitrogen atom is optionally substituted by (1-4C)alkyl, hydroxy(1-4C)alkyl, (1-2C)alkoxy-(1-4C)alkyl, or (1-4C)alkanoyl;
- or
- (v) a 4-7 membered heterocyclic group which is linked via a carbon atom;
- and R4 is a group —NR17R18, wherein R17 and R18 are linked to form a 4, 5, 6 or 7 membered heterocyclic ring which optionally comprises, in addition to the nitrogen atom to which R17 and R18 are attached, one or two further heteroatoms selected from O, N or S, and wherein any S atoms that are present may be optionally oxidised to form an SO or SO2 group, and wherein any carbon atom present in the ring is optionally substituted by oxo, halo, hydroxy, cyano, (1-4C)alkyl, hydroxy(1-4C)alkyl, (1-4C)alkoxy, (1-2C)alkoxy-(1-4C)alkyl, (1-4C)alkanoyl, (1-4C)alkanesulfonyl, (1-4C)alkoxycarbonyl, (1-6C)alkylaminocarbonyl or di-(1-6C)alkylaminocarbonyl and any available nitrogen atom present in the ring is optionally substituted by (1-4C)alkyl, hydroxy(1-4C)alkyl, (1-2C)alkoxy-(1-4C)alkyl, or (1-4C)alkanoyl;
- or a pharmaceutically acceptable salt thereof.
28 more elements
Dependencies are inferred from the claim text.